ALEXANDER KAY to Tuberculosis, Multidrug-Resistant
This is a "connection" page, showing publications ALEXANDER KAY has written about Tuberculosis, Multidrug-Resistant.
Connection Strength
2.532
-
HIV-associated drug-resistant TB: expanded treatment options and emerging threats. Curr Opin HIV AIDS. 2026 Mar 01; 21(2):172-179.
Score: 0.865
-
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev. 2020 08 27; 8:CD013359.
Score: 0.598
-
Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing. Nat Commun. 2026 Jun 11; 17(1).
Score: 0.223
-
Application of FreezeTB, a targeted nanopore sequencing assay, for identification of drug resistance and lineages among pulmonary tuberculosis cases in Alaska. Microbiol Spectr. 2026 Jan 06; 14(1):e0233525.
Score: 0.215
-
Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2023 07 15; 208(2):130-131.
Score: 0.182
-
Baseline assessment of pharmacovigilance activities in four sub-Saharan African countries: a perspective on tuberculosis. BMC Health Serv Res. 2021 Oct 08; 21(1):1062.
Score: 0.161
-
Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1095-1102.
Score: 0.150
-
Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019 06 01; 23(6):645-662.
Score: 0.137